Alessandro Pancrazzi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5718846/publications.pdf

Version: 2024-02-01

54 papers	5,061 citations	126907 33 h-index	182427 51 g-index
54 all docs	54 docs citations	54 times ranked	3588 citing authors

#	Article	IF	Citations
1	Lab tests for MPN. International Review of Cell and Molecular Biology, 2022, 366, 187-220.	3.2	1
2	Comparison of serologic and molecular SARS-CoV 2 results in a large cohort in Southern Tuscany demonstrates a role for serologic testing to increase diagnostic sensitivity. Clinical Biochemistry, 2020, 84, 87-92.	1.9	14
3	Elevated monocyte distribution width in COVID-19 patients: The contribution of the novel sepsis indicator. Clinica Chimica Acta, 2020, 509, 22-24.	1.1	42
4	Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia, 2020, 34, 2234-2237.	7.2	34
5	International external quality assurance of JAK2 V617F quantification. Annals of Hematology, 2019, 98, 1111-1118.	1.8	3
6	Clonal architecture of JAK2<scp>V617F</scp> mutated cells during treatment with ruxolitinib. Hematological Oncology, 2018, 36, 357-359.	1.7	0
7	Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea. Blood Cancer Journal, 2018, 8, 122.	6.2	25
8	Recommendations for molecular testing in classical Ph1-neg myeloproliferative disordersâ€“A consensus project of the Italian Society of Hematology. Leukemia Research, 2017, 58, 63-72.	0.8	25
9	Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis. Blood, 2017, 129, 3227-3236.	1.4	137
10	Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood Advances, 2016, 1, 21-30.	5.2	243
11	Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. American Journal of Hematology, 2016, 91, 918-922.	4.1	47
12	A data-driven network model of primary myelofibrosis: transcriptional and post-transcriptional alterations in CD34+ cells. Blood Cancer Journal, 2016, 6, e439-e439.	6.2	16
13	Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group. American Journal of Hematology, 2016, 91, 681-686.	4.1	80
14	Tie2 Expressing Monocytes in the Spleen of Patients with Primary Myelofibrosis. PLoS ONE, 2016, 11, e0156990.	2.5	3
15	JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib. Blood, 2015, 125, 3352-3353.	1.4	41
16	Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: an observational, hypothesis-generating study. Drug Design, Development and Therapy, 2015, 9, 2687.	4.3	4
17	Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. Pathology Research and Practice, 2015, 211, 341-343.	2.3	5
18	Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis. Blood Cancer Journal, 2015, 5, e360-e360.	6.2	72

#	Article	IF	Citations
19	Mutational Landscape of Patients with Myelofibrosis That Do Not Harbor Mutations in JAK2, MPL and Calreticulin Driver Genes. Blood, 2015, 126, 4091-4091.	1.4	2
20	CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. Leukemia, 2014, 28, 1494-1500.	7.2	248
21	Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. Leukemia, 2014, 28, 1052-1059.	7.2	66
22	Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood, 2014, 123, 1552-1555.	1.4	346
23	The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. Leukemia, 2014, 28, 1804-1810.	7.2	263
24	Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. Leukemia, 2013, 27, 2032-2039.	7.2	96
25	Mutations and prognosis in primary myelofibrosis. Leukemia, 2013, 27, 1861-1869.	7.2	653
26	Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. Haematologica, 2013, 98, e101-e102.	3.5	24
27	Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation. Blood, 2013, 121, 360-368.	1.4	102
28	Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. Blood, 2013, 121, 4388-4395.	1.4	83
29	Effect of the Number of Prognostically Relevant Mutated Genes on Survival and Leukemia Progression in Primary Myelofibrosis. Blood, 2013, 122, 104-104.	1.4	3
30	Targeted Cancer Exome Sequencing Discovers Novel Recurrent Mutations In MPN. Blood, 2013, 122, 4099-4099.	1.4	0
31	Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia, 2011, 25, 1834-1839.	7.2	59
32	Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis. Blood, 2011, 118, 2069-2076.	1.4	144
33	Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. Haematologica, 2011, 96, 315-318.	3.5	160
34	Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica, 2010, 95, 1435-1438.	3.5	41
35	CXCR4â€independent rescue of the myeloproliferative defect of the gata1^{low} myelofibrosis mouse model by AplidinÂ®. Journal of Cellular Physiology, 2010, 225, 490-499.	4.1	16
36	Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. Leukemia, 2010, 24, 1533-1537.	7.2	22

#	Article	IF	Citations
37	Increased Risk of Lymphoid Neoplasms in Patients with Philadelphia Chromosomeâ€“Negative Myeloproliferative Neoplasms. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2068-2073.	2.5	100
38	Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. Blood, 2009, 114, 1477-1483.	1.4	196
39	A Sensitive Detection Method for MPLW515L or MPLW515K Mutation in Chronic Myeloproliferative Disorders with Locked Nucleic Acid-Modified Probes and Real-Time Polymerase Chain Reaction. Journal of Molecular Diagnostics, 2008, 10, 435-441.	2.8	47
40	Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia. Haematologica, 2008, 93, 41-48.	3.5	146
41	Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood, 2008, 112, 844-847.	1.4	216
42	B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. Haematologica, 2007, 92, 258-259.	3.5	26
43	Prospective identification of high-risk polycythemia vera patients based on JAK2V617F allele burden. Leukemia, 2007, 21, 1952-1959.	7.2	328
44	Anaemia characterises patients with myelofibrosis harbouring MplW515L/Kmutation. British Journal of Haematology, 2007, 137, 244-247.	2.5	153
45	MicroRNA expression profile in granulocytes from primary myelofibrosis patients. Experimental Hematology, 2007, 35, 1708.e1-1708.e12.	0.4	71
46	Molecular Profiling of CD34+Cells in Idiopathic Myelofibrosis Identifies a Set of Disease-Associated Genes and Reveals the Clinical Significance of Wilms' Tumor Gene 1 (WT1). Stem Cells, 2007, 25, 165-173.	3.2	111
47	Inconsistencies in the association between the JAK2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases. British Journal of Haematology, 2006, 132, 652-654.	2.5	11
48	A quantitative assay for JAK2V617F mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis. Leukemia, 2006, 20, 1055-1060.	7.2	68
49	Influence of the Jak2V617F Mutational Load at Diagnosis on Major Clinical Aspects in Patients with Polycythemia Vera.. Blood, 2006, 108, 5-5.	1.4	14
50	A pathobiologic pathway linking thrombopoietin, GATA-1, and TGF-Î²1 in the development of myelofibrosis. Blood, 2005, 105, 3493-3501.	1.4	103
51	Variegation of the phenotype induced by the Gata1low mutation in mice of different genetic backgrounds. Blood, 2005, 106, 4102-4113.	1.4	32
52	Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. Leukemia, 2005, 19, 1847-1849.	7.2	236
53	Abnormalities of GATA-1 in Megakaryocytes from Patients with Idiopathic Myelofibrosis. American Journal of Pathology, 2005, 167, 849-858.	3.8	62
54	PRV-1 , erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. British Journal of Haematology, 2004, 127, 214-219.	2.5	21